Immunitybio | search
Click here to view Immunitybio news from 60+ newspapers.
Bookmark or Share- ImmunityBio Expands Manufacturing Capacity with State-of-the-Art ...About ImmunityBio ImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s broad immunotherapy and cell therapy platforms—including Antibody cytokine fusion proteins, synthetic immunomodulators ...
- Patrick Soon-Shiong's ImmunityBio bags FDA nod for bladder cancer drugImmunityBio believes Anktiva will largely be prescribed by urologists or specialized urologic oncologists. The company has assembled a commercial team of about 60 people, including a sales force ...
- Immunotherapy by ImmunityBio - Cancer Vaccine ResearchImmunityBio’s platforms address the entire immune system, harnessing the power of both innate and adaptive functions of the immune system by activation of ‘first responder’ natural killer (NK) cells, T cells, and macrophages, and establishment of immune memory by dendritic cells. We believe this comprehensive immunotherapy approach holds ...
- ImmunityBio, Inc. (IBRX) - Yahoo FinanceImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its ...
- ImmunityBio Announces FDA Approval of ANKTIVAImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of ...
More
